Ophthalmic and eye Rx products

US pharmaceutical-grade sodium hyaluronate manufacturer and CDMO; only US-based producer of injectable-grade HA via microbial fermentation; >20 commercially approved HA products including ophthalmic OVDs; producing since 1994.

German glass technology company (HQ Mainz); one of the most unusual corporate structures in global manufacturing: SCHOTT AG is 100% owned by the Ernst-Abbe Stiftung — a non-profit foundation established by optical pioneer Ernst Abbe in Jena, 1889. The foundation channels profits to employee welfare and scientific research. SCHOTT invented CERAN® glass-ceramic cooktop panels in 1971; has sold over 200 million units; estimates 55% of global qualified glass-ceramic cooktop market. ALL CERAN glass is melted at the Mainz, Germany facility using a proprietary controlled crystallization process that converts lithium aluminosilicate glass into the distinctive black glass-ceramic. SCHOTT also produces: ZEISS optical glass (same Jena/Schott historical partnership), pharmaceutical glass vials and syringes (world's largest producer), mirror blanks for the James Webb Space Telescope, and specialty glass for nuclear waste storage. A foundation-owned German company with no shareholders has ~55% of the global induction and electric cooktop glass market and also makes the largest telescope mirrors ever built.

US biopharmaceutical; acquired Allergan 2020; markets Restasis (cyclosporine 0.05% ophthalmic emulsion) for dry-eye disease; historically vertically integrated cyclosporine A API supply.

Merck KGaA (Darmstadt; family-owned since 1668; Life Science division ~$9B revenue) produces CHO cell culture media through its MilliporeSigma brand in North America and SAFC (Sigma-Aldrich Formulation & Custom manufacturing) globally. SAFC Biosciences is the custom media manufacturing arm that produces proprietary 'black box' formulations for major biopharmaceutical companies under NDA — meaning a significant fraction of industry media demand is manufactured exclusively by Merck KGaA under confidential contracts. Merck KGaA's media manufacturing sites include St. Louis, Missouri (Sigma-Aldrich legacy site) and Martillac, France (custom bioscience manufacturing). The same Merck KGaA Darmstadt organization manufactures EUV photoresists (display and semiconductor), liquid crystals for flat panels, and Fractogel chromatography resins — a German family-controlled conglomerate touching monoclonal antibody media, display materials, and semiconductor chemicals from one Hessen campus.

German pharma packaging specialist; ~30–35% global pharma glass packaging alongside Schott; acquired Bormioli Pharma Dec 2024; also produces LDPE ophthalmic dropper bottles (System A).

American filtration, separation, and purification technology company (Port Washington, NY; Danaher Corporation subsidiary since 2015 acquisition for $13.8B); world's second-largest pharmaceutical sterilizing filter manufacturer under the Supor® (PES), Fluorodyne® EX (PVDF), and Emflon® (PTFE) brands. Pall Corporation was founded in 1946 by Dr. David Pall, a British-born scientist who invented the first practical fluid filtration membrane for aircraft jet fuel systems during WWII — technology originally developed for military aviation now forms the basis of pharmaceutical sterile filtration. Pall's acquisition by Danaher — which also owns Cytiva (former GE Healthcare Life Sciences, bioreactors and chromatography) — means a single US conglomerate controls approximately 35-40% of the critical tools and materials used in both IV fluid manufacturing and biopharmaceutical drug production.

Lonza Group AG (Visp, Switzerland; SIX: LONN; ~CHF 6.7B revenue) is the world's largest pharmaceutical and biotech CDMO (Contract Development and Manufacturing Organization). Primary business is biologic drug manufacturing (mammalian cell culture, microbial fermentation) for pharma clients. Manufactured Moderna COVID-19 mRNA. Sold Specialty Ingredients (biocides: benzalkonium chloride, quats) to Arxada in 2021. Capsules and health ingredients division (HPMC and gelatin capsules) is the world's largest hard capsule manufacturer.

European API manufacturer spun off from Sanofi 2022; complex API synthesis including prostaglandin analogues (latanoprost, travoprost) at Frankfurt site; ~20–25% branded prostaglandin API supply.

German life sciences company that manufactured the world's first industrial nitrocellulose membrane in 1960 in Göttingen. Its Unisart® CN series is one of the two dominant global LFA membrane brands. Key OEM supplier to virtually every major rapid test manufacturer.

Taiwanese specialty pharmaceutical API company (HQ Taipei; listed on Taiwan Stock Exchange); specializes in chiral synthesis of complex pharmaceutical intermediates and APIs including prostaglandin analogues (latanoprost, bimatoprost, travoprost) for ophthalmic glaucoma treatment. Chirogate's prostaglandin API capability is one of a very small number of commercial-scale chiral prostaglandin synthesis operations globally. Prostaglandin analogues require control of multiple stereocenters — including the stereochemistry of the cyclopentyl ring system and aliphatic chain — in molecules that cost $1M+ per kilogram due to the extreme chemical synthesis challenge. Chirogate's expertise in asymmetric synthesis for prostaglandins demonstrates that small Taiwanese specialty chemistry companies can hold critical supply chain positions in global pharmaceutical markets — ophthalmic surgeons worldwide depend on APIs from a company most of their patients have never heard of.

Washington DC-based conglomerate that owns Cytiva (Whatman brand — nitrocellulose membranes, glass fiber pads), IDT (oligonucleotide probes), and Pall Corporation (filtration). Controls an extraordinary concentration of IVD supply chain chokepoints through acquisitions across multiple independent critical nodes.

Indian generic pharmaceutical company and the world's largest generic inhaler manufacturer by volume. Pioneer of generic salbutamol inhalers in India (1978). Manufactures generic pMDIs at scale. Received FDA final approval for generic Proventil HFA. Critical supplier during COVID-19 when global inhaler demand surged.

Japanese food and chemical company known for mayonnaise; also a major global supplier of pharmaceutical-grade sodium hyaluronate via Streptococcus fermentation at Torii plant — a classic dual-use supplier.

Stepan Company (Northfield IL; NYSE: SCL; ~$2.3B revenue) is the largest US-based surfactant manufacturer. Stepan's Surfactants segment (approximately 65% of revenue) produces SLES and a broad range of anionic, nonionic, and amphoteric surfactants for personal care, detergent, agricultural, and industrial markets. Key US plants: Maywood NJ (fatty acid sulfonation), Elwood IL, and Millsdale IL (largest plant — Joliet IL area). International plants in Voreppe France, Manno Switzerland, Nanjing China, Pasir Gudang Malaysia, and Ecatepec Mexico. Stepan holds exclusive rights to produce certain specialty low-1,4-dioxane SLES grades — a competitive advantage as New York and other states tighten dioxane limits.

Italian pharmaceutical glass packaging company (NYSE: STVN since June 2021 IPO; family-owned by Stevanato family; ~€800M revenue 2023); headquartered in Piombino Dese, Veneto, Italy. Stevanato is the world's second-largest pharmaceutical glass primary packaging manufacturer and the largest independent vial converter — buying borosilicate glass tubing from SCHOTT and converting it to finished pharmaceutical vials, syringes, and cartridges. Also manufactures the vial-forming machines used in vial conversion (through subsidiary Spami). Stevanato's Piombino Dese campus is one of the highest-capacity pharmaceutical glass vial conversion sites in Europe. Major supplier to COVID-19 vaccine programs. Expanding Fishers, Indiana (US) greenfield glass/plastic hybrid plant (opening 2025) for North American market.

US generic pharmaceutical company (spun off from Pfizer/Mylan 2020); first FDA approval for generic Restasis (cyclosporine ophthalmic emulsion) February 2022.

Indian biotechnology and pharmaceutical company (NSE: BIOCON; Biocon Biologics listed separately; HQ Bangalore; ~₹150B revenue for Biocon group); Biocon is India's largest biopharmaceutical company and a major producer of complex small molecules and biologics including cyclosporine A API and immunosuppressants. Biocon Limited was founded in 1978 by Kiran Mazumdar-Shaw — one of India's most prominent female entrepreneurs — as an enzyme fermentation company, starting in a garage with ₹10,000 in capital. Today Biocon is a ~$3B revenue pharmaceutical company producing insulin biosimilars, cancer biologics, and complex small molecule APIs including cyclosporine A. The same Biocon that produces the cyclosporine A API for generic dry eye drops also produces trastuzumab biosimilar (Herceptin equivalent for breast cancer) and insulin analogs for diabetes — one Indian startup from 1978 spanning oncology, endocrinology, and ophthalmology API supply chains.

Indian pharmaceutical API manufacturer (NSE: DIVISLAB, HQ Hyderabad; ~₹75B revenue); one of India's largest and most technically sophisticated pharmaceutical API producers, specializing in complex APIs including fluoroquinolones (ciprofloxacin, ofloxacin, levofloxacin), carotenoids (nutraceuticals), and custom synthesis for branded pharmaceutical companies. Divi's Laboratories has never been involved in a major USFDA warning letter or import alert (unusual for an Indian API company of its scale) — maintaining essentially clean regulatory compliance across its multiple Visakhapatnam, Andhra Pradesh production facilities. Divi's produces fluoroquinolone APIs including ciprofloxacin HCl for ophthalmic applications for global generic pharmaceutical customers. Divi's is also one of India's most consistently profitable pharmaceutical companies — its focus on volume API production at high quality has created a near-uninterruptible supply chain position across multiple essential medicines.